Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568160 | 0.96 | ALDH1A1 (0.52) | ALDH1A1NPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL2599858 | 0.84 | NPY5R (0.46) | ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL2943702 | 0.84 | NPY5R (0.46) | ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4516164 | 0.81 | L3MBTL1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL403484 | 0.81 | ALDH1A1 (0.48) | ALDH1A1NPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL17872620 | 0.81 | POLB (0.43) | ALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL17872617 | 0.81 | POLB (0.43) | ALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL4206666 | 0.80 | MAPT (0.46) | ALDH1A1NPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL2130275 | 0.80 | ALDH1A1 (0.47) | ALDH1A1NPC1SMN1; SMN2MAPTTSHR | |
| SCHEMBL12513671 | 0.79 | NPY5R (0.45) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| EP-2408767-B1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2013-07-10 | — | — | EP | disclosed |
| EP-2408767-B1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2013-07-10 | — | — | EP | disclosed |
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBRCK A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBRCK A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBRCK A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| EP-2408767-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. Lundbeck A/S (DK) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108052-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108052-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 2010-09-23 | — | — | WO | disclosed |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | SEKI MASAHIKO | 2009-01-22 | — | — | US | disclosed |
| US-7439368-B2 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-07 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| CN-1842528-A | Process for preparing 3-acylaminobenzofuran-2-carboxylic acid derivatives | TANABE SEIYAKU CO (JP) | 2006-10-04 | — | — | CN | disclosed |
| US-20060173188-A1 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1640373-A1 | PROCESS FOR PRODUCING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | ALDH1A1 1270/4885NPC1 1778/4885SMN1; SMN2 4312/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | ALDH1A1 3204/4885NPC1 4319/4885SMN1; SMN2 2952/4885 |
| US-20070129361-A1 | LACTAM-CONTAINING DIAMINOALKYL, Beta-AMINOACIDS, Alpha-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | PEPD, XPNPEP1, METAP1 | ALDH1A1 1204/4885NPC1 3393/4885SMN1; SMN2 2742/4885 |
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | NPY5R, NPY1R, NPY2R | ALDH1A1 4710/4885NPC1 2211/4885SMN1; SMN2 3161/4885 |
| US-20060173188-A1 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | F12, F3, F11 | ALDH1A1 661/4885NPC1 3078/4885SMN1; SMN2 4062/4885 |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | F12, F3, F11 | ALDH1A1 690/4885NPC1 2896/4885SMN1; SMN2 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.